IFG Advisory LLC Sells 114 Shares of Eli Lilly and Company (NYSE:LLY)

IFG Advisory LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,988 shares of the company’s stock after selling 114 shares during the period. IFG Advisory LLC’s holdings in Eli Lilly and Company were worth $1,742,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Thompson Investment Management Inc. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at about $27,000. Retirement Group LLC increased its holdings in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares in the last quarter. Cornerstone Planning Group LLC bought a new position in Eli Lilly and Company in the 2nd quarter worth approximately $33,000. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company during the 3rd quarter worth $35,000. Finally, Optiver Holding B.V. bought a new position in Eli Lilly and Company in the 3rd quarter valued at $36,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $778.69 on Thursday. The stock has a market capitalization of $739.88 billion, a PE ratio of 134.26, a P/E/G ratio of 1.70 and a beta of 0.34. The business has a fifty day moving average price of $727.96 and a two-hundred day moving average price of $636.01. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a fifty-two week low of $334.58 and a fifty-two week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.09 earnings per share. As a group, equities analysts predict that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 14,388 shares of the firm’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $630.28, for a total value of $9,068,468.64. Following the completion of the sale, the insider now directly owns 99,754,422 shares in the company, valued at approximately $62,873,217,098.16. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold a total of 195,055 shares of company stock valued at $125,254,657 over the last ninety days. 0.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Bank of America increased their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Truist Financial reaffirmed a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $689.52.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.